Quantcast

Oncolytics Biotech® Inc. Announces Details of 2014 Annual Meeting of Shareholders

June 16, 2014

CALGARY, June 16, 2014 /PRNewswire/ – Oncolytics Biotech Inc. (TSX: ONC,
NASDAQ: ONCY) announced today that its 2014 Annual Meeting of
Shareholders will be held on Wednesday June 18(th), 2014 at 4:30pm ET at the TMX Broadcast Centre, 130 King Street West,
Toronto, ON

Following the business portion of the meeting, Dr. Brad Thompson,
President and CEO of Oncolytics, will discuss recent progress in the
development of REOLYSIN(®) as a potential cancer therapeutic.

A live audio webcast of the presentation will begin at approximately
4:45 p.m. ET at: http://event.on24.com/r.htm?e=693678&s=1&k=6D220DB1FF9B2F2B104E2DB0F5F9555D or on the company’s website at www.oncolyticsbiotech.com. It is recommended that listeners log on 10 minutes in advance of the
presentation to register and download any necessary software.

An audio replay will be accessible following the presentation at http://www.oncolyticsbiotech.com/for-investors/presentations.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the
development of oncolytic viruses as potential cancer therapeutics.
Oncolytics’ clinical program includes a variety of human trials
including a Phase III trial in head and neck cancers using REOLYSIN,
its proprietary formulation of the human reovirus. For further
information about Oncolytics, please visit: www.oncolyticsbiotech.com.

The presentation and webcast times are subject to change. This release
and the presentation related thereto contain forward-looking statements
which involve known and unknown risks, delays, uncertainties and other
factors not under the Company’s control and which may cause actual
results, performance or achievements of the Company to be materially
different from the results, performance or expectations implied by
these forward-looking statements
. Such risks and uncertainties include, among others, the efficacy of
REOLYSIN as a cancer treatment, the success and timely completion of
clinical studies and trials, uncertainties related to the research and
development of pharmaceuticals and uncertainties related to the
regulatory process. Investors should consult the Company’s quarterly
and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to the
forward-looking statements. Investors are cautioned against placing
undue reliance on forward-looking statements. The Company does not
undertake to update these forward-looking statements, except as
required by applicable laws.

SOURCE Oncolytics Biotech Inc.


Source: PR Newswire



comments powered by Disqus